Skip to main content

Let them drink wine: A Bastille Day toast to healthy drinking

Marie Antoinette may be popularly credited with spurring the French revolution (and losing her head) with her response to the shortage of bread, but a closer look at the events leading up the storming of the Bastille on July 14, 1789 reveals that access to affordable wine was perhaps an even more important factor. In May a national assembly was convened to air grievances of the common people and demand formation of a constitution. A series of poor harvests and widespread food shortages contributed to general unrest, but the Bastille became a target both because “political” prisoners were housed there on arbitrary orders from the king, and also because it was an armory. But it was not the storming of the Bastille that was the first act of civil unrest in the French revolution, it was attacks on the customs houses where duties on wine were collected.


Wine, however, was not in particularly short supply in the 1780’s. The issue was a tax that was collected on wine as it was brought into the city, which had created an opportunity for enterprising publicans who set up shop just outside the Paris city gates. Affordable wine had thereby been generally available without a long journey at the end of a day’s work in the city. As one member of the legislature, Etienne Chevalier put it in 1789: “Wine is the basis of survival for the poor citizens of Paris. When bread, meat, and other foods are too expensive, he turns to wine; he nourishes and consoles himself with it.” But Paris, a walled city at the time, was growing, and as the walls were moved outward it became increasingly difficult for the “poor citizens of Paris” to maintain easy access to this important source of nutrition and comfort. So it was the customs houses at the gates of Paris that were targeted first in the revolution.

Some 300 years later, the French paradox would confirm the health benefits of regular consumption of wine with the evening meal. If there is a lesson in this historical nugget, perhaps it is this: Let them drink wine. A good baguette wouldn’t hurt either.

Comments

Popular posts from this blog

Revisiting resveratrol: new findings rekindle anti-aging debate

Just when we thought the bloom was off the rosé for resveratrol, the anti-oxidant polyphenol from red wine with multiple anti-aging properties, along comes new research giving life to the debate. But first a bit of background: As I detailed in my book Age Gets Better with Wine , it is well-documented that wine drinkers live longer and have lower rates of many diseases of aging. Much or the credit for this has been given to resveratrol, though there isn’t nearly enough of it in wine to explain the effects. Nevertheless, I dubbed it the “miracle molecule” and when it was reported to activate a unique life-extension phenomenon via a genetic trigger called SIRT, an industry was born, led by Sirtris Pharmaceuticals, quickly acquired by pharma giant Glaxo. The hope was that resveratrol science could lead to compounds enabling people to live up to 150 years and with a good quality of life. But alas, researchers from other labs could not duplicate the results, and clinical studies disa...

new resveratrol revelations

What a year it has been for resveratrol, the polyphenol molecule from red wine. Last year at this time it was the toast of the town, having been credited with triggering a metabolic change leading to increased lifespan in experimental models, then catapulted into the limelight as a potential cancer cure with clinical trials under the auspices of pharma giant GlaxoSmithKline. Sales of resveratrol supplements were skyrocketing, with audacious claims about weight loss, brain power, and longevity, never mind that none of this had been proven in humans. But with the new year came new controversy. Two of Glaxo’s competitors, Pfizer and Amgen, published their own studies on resveratrol, concluding that the longevity effect was false, an artifact of the testing method. What few clinical trials there are in humans revealed that it is poorly absorbed and doesn’t last very long in the body anyway. Then in November Glaxo abruptly announced the suspension of the clinical trial and all further devel...